Biotest AG: Biotest AG: Annual General Meeting approves dividend increase
Biotest AG / Key word(s): AGM/EGM
12.05.2011 / 17:19
Biotest AG: Annual General Meeting approves dividend increase
- Approved dividend of EUR 0.38 per ordinary share and EUR 0.44 per
preference share
- Total distribution payment up to more than EUR 4.7 million
Dreieich/ Frankfurt am Main, May 12, 2011 - Shareholders of Biotest AG with
84.1 % of shareholder present, approved a dividend of EUR 0.38 per ordinary
share for 2010 and a dividend of EUR 0.44 per preference share at the
company's Annual General Meeting held today in Frankfurt/ Main. Compared to
the previous year, this represents an increase by 11.8% for the ordinary
shares and an increase of 10% for the preference shares. It corresponds to
a total dividend payout of about EUR 4.7 million.
The Annual General Meeting approved the ratification of the acts of
management of the members of the Management Board and of the members of the
Supervisory Board for 2010 and approved all other proposals put forward by
the Management Board and Supervisory Board.
About 130 shareholders and guests took part in the Annual General Meeting.
The full version of Prof. Dr. Gregor Schulz's speech is online available
at:
www.biotest.de/ Investor Relations/ AGM
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
application of clinical immunology, haematology and intensive medicine. In
its Plasma Protein segment, Biotest develops and markets immunoglobulins,
coagulation factors and albumins based on human blood plasma. These are
used for diseases of the immune and haematopoietic systems. In the
Biotherapeutic segment, Biotest researches into the clinical development of
monoclonal antibodies, including in the indications of rheumatoid arthritis
and cancer of plasma cells. Biotest has more than 1.600 employees
worldwide. The preference shares of Biotest AG are listed in the SDAX on
the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
End of Corporate News
---------------------------------------------------------------------
12.05.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
124463 12.05.2011